


PHARMACEUTICAL 2022



XBiotech Inc. Rank 35 of 475







PHARMACEUTICAL 2022



XBiotech Inc. Rank 35 of 475



The relative strengths and weaknesses of XBiotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XBiotech Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 91% points. The greatest weakness of XBiotech Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 8.4% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 438% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	246,870
Cost of Goods Sold	5,820
Intangible Assets	0
Liabilities, Current	3,453
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	705
Other Expenses	-8,044
Other Liabilities	2,339
Other Net Income	-376
Property and Equipment	28,307
Research and Development	28,268
Revenues	18,394
Selling, General and Administrative Expense	9,388

Output Variable	Value in 1000 USD
Assets	275,177
Liabilities	5,792
Expenses	35,432
Stockholders Equity	269,385
Net Income	-17,414
Comprehensive Net Income	-17,062
Economic Capital Ratio	162%